Zhengfang Yi

8.1k total citations
117 papers, 6.2k citations indexed

About

Zhengfang Yi is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Zhengfang Yi has authored 117 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Molecular Biology, 33 papers in Oncology and 19 papers in Cancer Research. Recurrent topics in Zhengfang Yi's work include Cancer Mechanisms and Therapy (11 papers), Wound Healing and Treatments (10 papers) and Electrospun Nanofibers in Biomedical Applications (10 papers). Zhengfang Yi is often cited by papers focused on Cancer Mechanisms and Therapy (11 papers), Wound Healing and Treatments (10 papers) and Electrospun Nanofibers in Biomedical Applications (10 papers). Zhengfang Yi collaborates with scholars based in China, United States and United Kingdom. Zhengfang Yi's co-authors include Mingyao Liu, Xiufeng Pang, Jiang Chang, Chengtie Wu, Bharat B. Aggarwal, Jian Luo, Fang Lv, Sung‐Gook Cho, Dong Zhai and Tingfang Yi and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Zhengfang Yi

115 papers receiving 6.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhengfang Yi China 46 2.9k 1.1k 1.0k 859 658 117 6.2k
Lei Qiang China 44 2.2k 0.8× 1.1k 0.9× 706 0.7× 614 0.7× 269 0.4× 151 5.3k
Wenwen Zhao China 37 1.5k 0.5× 850 0.7× 804 0.8× 226 0.3× 257 0.4× 149 4.3k
Jian Luo China 48 3.9k 1.4× 396 0.3× 248 0.2× 1.0k 1.2× 484 0.7× 133 6.3k
Jie Gao China 43 2.9k 1.0× 1.8k 1.5× 1.7k 1.7× 882 1.0× 248 0.4× 238 6.4k
Ann Y. Park United States 3 1.6k 0.6× 463 0.4× 373 0.4× 531 0.6× 170 0.3× 4 3.7k
Gu He China 44 3.0k 1.1× 500 0.4× 563 0.5× 551 0.6× 1.7k 2.6× 243 6.8k
Mintu Pal India 37 1.4k 0.5× 905 0.8× 504 0.5× 531 0.6× 160 0.2× 88 4.4k
Juan Antonio Marchal Spain 44 2.6k 0.9× 1.4k 1.2× 957 0.9× 1.0k 1.2× 524 0.8× 250 6.3k
Maryam Moghaddam Matin Iran 33 2.3k 0.8× 882 0.8× 681 0.7× 484 0.6× 265 0.4× 237 4.5k
Mehdi Dadashpour Iran 38 1.3k 0.4× 693 0.6× 915 0.9× 297 0.3× 186 0.3× 77 3.2k

Countries citing papers authored by Zhengfang Yi

Since Specialization
Citations

This map shows the geographic impact of Zhengfang Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhengfang Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhengfang Yi more than expected).

Fields of papers citing papers by Zhengfang Yi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhengfang Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhengfang Yi. The network helps show where Zhengfang Yi may publish in the future.

Co-authorship network of co-authors of Zhengfang Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Zhengfang Yi. A scholar is included among the top collaborators of Zhengfang Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhengfang Yi. Zhengfang Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Yi, Xiaodong Wang, Lufeng Yang, et al.. (2025). Targeting BCMA in multiple myeloma: designs, challenges, and future directions. Cancer Immunology Immunotherapy. 74(3). 77–77. 6 indexed citations
2.
Guo, Weikai, et al.. (2024). A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma. Molecular Cancer Therapeutics. 24(1). 81–92.
3.
Wu, Min, Lin Zhang, Siyu Wang, et al.. (2024). IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells. Cellular Oncology. 47(5). 1797–1809. 1 indexed citations
4.
Wu, Min, Li Shen, Yunqi Li, et al.. (2023). Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer. Journal of Medicinal Chemistry. 66(24). 16917–16938. 7 indexed citations
5.
Zhang, Qiansen, Ying Miao, Xuan Yin, et al.. (2022). Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer. Clinical Cancer Research. 29(4). 815–830. 42 indexed citations
6.
Guo, Weikai, Qiansen Zhang, Peng He, et al.. (2020). Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth. Journal of Medicinal Chemistry. 63(2). 676–695. 25 indexed citations
7.
Li, Yunqi, Yuan He, Ting Shao, et al.. (2019). Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin. Journal of Medicinal Chemistry. 62(10). 4949–4966. 29 indexed citations
8.
Jiang, Yuqi, Yiming Han, Jie Wang, et al.. (2019). Space-Oriented Nanofibrous Scaffold with Silicon-Doped Amorphous Calcium Phosphate Nanocoating for Diabetic Wound Healing. ACS Applied Bio Materials. 2(2). 787–795. 32 indexed citations
9.
Yu, Qingqing, Yiming Han, Xiaocheng Wang, et al.. (2018). Copper Silicate Hollow Microspheres-Incorporated Scaffolds for Chemo-Photothermal Therapy of Melanoma and Tissue Healing. ACS Nano. 12(3). 2695–2707. 179 indexed citations
10.
Wang, Xiaocheng, Fang Lv, Tian Li, et al.. (2017). Electrospun Micropatterned Nanocomposites Incorporated with Cu2S Nanoflowers for Skin Tumor Therapy and Wound Healing. ACS Nano. 11(11). 11337–11349. 202 indexed citations
11.
Huang, Chen, Li-Fang Yu, Fang Lv, et al.. (2016). Novel 3,4- seco bile acid diamides as selective anticancer proliferation and migration agents. European Journal of Medicinal Chemistry. 122(2). 574–583. 10 indexed citations
12.
Zhou, Wenbo, Yong Zhang, Weikai Guo, et al.. (2015). Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents. European Journal of Medicinal Chemistry. 96. 269–280. 21 indexed citations
13.
Hu, Meichun, Shihong Peng, Yundong He, et al.. (2015). Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer. Oncotarget. 6(17). 15348–15361. 68 indexed citations
14.
Luo, Wen, Jinsheng Weng, Li Zeng, et al.. (2014). PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-κB. Oncogenesis. 3(8). e114–e114. 46 indexed citations
15.
Chen, Jing, Jieqiong Wang, Lin Lei, et al.. (2011). Inhibition of STAT3 Signaling Pathway by Nitidine Chloride Suppressed the Angiogenesis and Growth of Human Gastric Cancer. Molecular Cancer Therapeutics. 11(2). 277–287. 148 indexed citations
16.
Lai, Li, Junchen Liu, Dong Zhai, et al.. (2011). Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor‐2. British Journal of Pharmacology. 165(4b). 1084–1096. 71 indexed citations
17.
Wu, Yuanyuan, Lijun He, Li Zhang, et al.. (2011). Anacardic Acid (6-Pentadecylsalicylic Acid) Inhibits Tumor Angiogenesis by Targeting Src/FAK/Rho GTPases Signaling Pathway. Journal of Pharmacology and Experimental Therapeutics. 339(2). 403–411. 64 indexed citations
18.
19.
Dong, Yujuan, Bojing Lu, Xiongwen Zhang, et al.. (2010). Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis. 31(12). 2097–2104. 145 indexed citations
20.
Yi, Zhengfang, Sung‐Gook Cho, Hui Zhao, et al.. (2008). A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c‐Src phosphorylation in VEGF‐induced human umbilical endothelial cells. International Journal of Cancer. 124(4). 843–852. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lei Qiang Breakdown of academic impact, for papers by Wenwen Zhao Breakdown of academic impact, for papers by Jian Luo Breakdown of academic impact, for papers by Jie Gao Breakdown of academic impact, for papers by Ann Y. Park Breakdown of academic impact, for papers by Gu He Breakdown of academic impact, for papers by Mintu Pal Breakdown of academic impact, for papers by Juan Antonio Marchal Breakdown of academic impact, for papers by Maryam Moghaddam Matin Breakdown of academic impact, for papers by Mehdi Dadashpour
Rankless by CCL
2026